Update on PSA Testing

View More View Less
  • 1 From the Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland.

The use of prostate-specific antigen (PSA) testing for prostate cancer screening has increased dramatically over the past decade. Determining the most efficient way to use PSA testing and how to interpret total PSA levels and changes in PSA values over time remain challenging. Guidelines for early detection of prostate cancer have a direct impact on the number of unnecessary tests performed and are critical for developing a successful screening approach for prostate cancer. The age at which PSA screening should begin, PSA testing intervals, and the importance of understanding fluctuations in PSA values over time are discussed in the framework of recent discoveries in the field. Results from ongoing randomized trials will confirm whether prostate cancer screening is an effective method for reducing deaths from prostate cancer and what approaches will provide the most cost-effective screening strategies.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Mark L. Gonzalgo, MD, PhD, Department of Urology, Phipps 560-A, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287. E-mail: gonzalgo@jhmi.edu
  • 1.

    Catalona WJ, Smith DS, Ratliff TL. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948954.

    • Search Google Scholar
    • Export Citation
  • 2.

    Catalona WJ, Richie JP, Ahmann FR. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:12831290.

    • Search Google Scholar
    • Export Citation
  • 3.

    Zhu H, Roehl KA, Antenor JA. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology 2005;66:547551.

    • Search Google Scholar
    • Export Citation
  • 4.

    Carter HB. Prostate cancers in men with low PSA levels—must we find them? N Engl J Med 2004;350:22922294.

  • 5.

    Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 2005;97:11321137.

    • Search Google Scholar
    • Export Citation
  • 6.

    Christensson A, Bjork T, Nilsson O. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100105.

    • Search Google Scholar
    • Export Citation
  • 7.

    Lilja H. Structure, function, and regulation of the enzyme activity of prostate-specific antigen. World J Urol 1993;11:188191.

  • 8.

    Catalona WJ, Partin AW, Slawin KM. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:15421547.

    • Search Google Scholar
    • Export Citation
  • 9.

    Roehl KA, Antenor JA, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml range. J Urol 2002;168:922925.

    • Search Google Scholar
    • Export Citation
  • 10.

    Raaijmakers R, Blijenberg BG, Finlay JA. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 2004;171:22452249.

    • Search Google Scholar
    • Export Citation
  • 11.

    Mohler J, Babaian RJ, Bahnson RR. The NCCN prostate cancer clinical practice guidelines in oncology, version 2, 2007. Available at: http://www.nccn.org/professionals/physician_gls/. Accessed June 24, 2007.

    • Search Google Scholar
    • Export Citation
  • 12.

    Benson MC, Whang IS, Pantuck A. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815816.

    • Search Google Scholar
    • Export Citation
  • 13.

    Semjonow A, Hamm M, Rathert P. Prostate-specific antigen corrected for prostate volume improves differentiation of benign prostatic hyperplasia and organ-confined prostatic cancer. Br J Urol 1994;73:538543.

    • Search Google Scholar
    • Export Citation
  • 14.

    Benson MC, McMahon DJ, Cooner WH. An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density. World J Urol 1993;11:206213.

    • Search Google Scholar
    • Export Citation
  • 15.

    Wolff JM, Boeckmann W, Effert PJ. Evaluation of patients with diseases of the prostate using prostate-specific antigen density. Br J Urol 1995;76:4146.

    • Search Google Scholar
    • Export Citation
  • 16.

    Epstein JI, Chan DW, Sokoll LJ. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160:24072411.

    • Search Google Scholar
    • Export Citation
  • 17.

    Catalona WJ, Richie JP, deKernion JB. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994;152:20312036.

    • Search Google Scholar
    • Export Citation
  • 18.

    Lujan M, Paez A, Llanes L. Prostate specific antigen density. Is there a role for this parameter when screening for prostate cancer? Prostate Cancer Prostatic Dis 2001;4:146149.

    • Search Google Scholar
    • Export Citation
  • 19.

    Taneja SS, Tran K, Lepor H. Volume-specific cutoffs are necessary for reproducible application of prostate-specific antigen density of the transition zone in prostate cancer detection. Urology 2001;58:222227.

    • Search Google Scholar
    • Export Citation
  • 20.

    Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin 2007;57:90104.

    • Search Google Scholar
    • Export Citation
  • 21.

    Thompson IM. Counseling patients with newly diagnosed prostate cancer. Oncology 2000;14:119126.

  • 22.

    Etzioni R, Cha R, Cowen ME. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. J Urol 1999;162:741748.

    • Search Google Scholar
    • Export Citation
  • 23.

    Ross KS, Carter HB, Pearson JD. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000;284:13991405.

    • Search Google Scholar
    • Export Citation
  • 24.

    Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology 2000;14:267272.

  • 25.

    Carter HB, Epstein JI, Chan DW. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997;277:14561460.

    • Search Google Scholar
    • Export Citation
  • 26.

    Hugosson J, Aus G, Lilja H. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol 2003;169:17201723.

    • Search Google Scholar
    • Export Citation
  • 27.

    Hugosson J, Aus G, Lilja H. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100:13971405.

    • Search Google Scholar
    • Export Citation
  • 28.

    Postma R, Roobol M, Schroder FH. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. Cancer 2004;100:968975.

    • Search Google Scholar
    • Export Citation
  • 29.

    Johansson JE, Andren O, Andersson SO. Natural history of early, localized prostate cancer. JAMA 2004;291:27132719.

  • 30.

    Carter HB, Landis PK, Metter EJ. Prostate-specific antigen testing of older men. J Natl Cancer Inst 1999;91:17331737.

  • 31.

    Walter LC, Bertenthal D, Lindquist K. PSA screening among elderly men with limited life expectancies. JAMA 2006;296:23362342.

  • 32.

    Roehrborn CG, Boyle P, Gould AL. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999;53:581589.

    • Search Google Scholar
    • Export Citation
  • 33.

    Roehrborn CG, McConnell J, Bonilla J. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000;163:1320.

    • Search Google Scholar
    • Export Citation
  • 34.

    Oesterling JE, Jacobsen SJ, Chute CG. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860864.

    • Search Google Scholar
    • Export Citation
  • 35.

    Morgan TO, Jacobsen SJ, McCarthy WF. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996;335:304310.

    • Search Google Scholar
    • Export Citation
  • 36.

    Eastham JA, Riedel E, Scardino PT. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003;289:26952700.

    • Search Google Scholar
    • Export Citation
  • 37.

    Carter HB, Pearson JD, Metter EJ. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:22152220.

    • Search Google Scholar
    • Export Citation
  • 38.

    Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994;152:11631167.

    • Search Google Scholar
    • Export Citation
  • 39.

    Carter HB, Pearson JD, Waclawiw Z. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995;45:591596.

    • Search Google Scholar
    • Export Citation
  • 40.

    Kadmon D, Weinberg AD, Williams RH. Pitfalls in interpreting prostate specific antigen velocity. J Urol 1996;155:16551657.

  • 41.

    Carter HB, Ferrucci L, Kettermann A. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:15211527.

    • Search Google Scholar
    • Export Citation
  • 42.

    Loeb S, Roehl KA, Catalona WJ. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 2007;177:899902.

    • Search Google Scholar
    • Export Citation
  • 43.

    Carter HB, Kettermann A, Ferrucci L, Landis P. Risk count assessment: a new concept for detection of life threatening prostate cancer during a window of curability. Urology 2007;in press.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 96 74 11
PDF Downloads 35 30 13
EPUB Downloads 0 0 0